University of Chicago, Chicago, Illinois, USA.
Anesth Analg. 2011 Mar;112(3):558-67. doi: 10.1213/ANE.0b013e31820568af. Epub 2010 Dec 14.
The possibility that μ opioid agonists can influence cancer recurrence is a subject of recent interest. Epidemiologic studies suggested that there were differences in cancer recurrence in breast and prostate cancer contingent on anesthetic regimens. In this study, we identify a possible mechanism for these epidemiologic findings on the basis of μ opioid receptor (MOR) regulation of Lewis lung carcinoma (LLC) tumorigenicity in cell and animal models.
We used human lung tissue and human non-small cell lung cancer (NSCLC) cell lines and evaluated MOR expression using immunoblot and immunohistochemical analysis. LLC cells were treated with the peripheral opioid antagonist methylnaltrexone (MNTX) or MOR shRNA and evaluated for proliferation, invasion, and soft agar colony formation in vitro and primary tumor growth and lung metastasis in C57BL/6 and MOR knockout mice using VisEn fluorescence mediated tomography imaging and immunohistochemical analysis.
We provide several lines of evidence that the MOR may be a potential target for lung cancer, a disease with high mortality and few treatment options. We first observed that there is ∼5- to 10-fold increase in MOR expression in lung samples from patients with NSCLC and in several human NSCLC cell lines. The MOR agonists morphine and [D-Ala(2), N-MePhe(4), Gly-ol]-enkephalin (DAMGO) increased in vitro LLC cell growth. Treatment with MNTX or silencing MOR expression inhibited LLC invasion and anchorage-independent growth by 50%-80%. Injection of MOR silenced LLC lead to a ∼65% reduction in mouse lung metastasis. In addition, MOR knockout mice do not develop significant tumors when injected with LLC in comparison with wild-type controls. Finally, continuous infusion of the peripheral opioid antagonist MNTX attenuates primary LLC tumor growth and reduces lung metastasis.
Taken together, our data suggest a possible direct effect of opiates on lung cancer progression, and provide a plausible explanation for the epidemiologic findings. Our observations further suggest a possible therapeutic role for opioid antagonists.
μ 阿片受体激动剂可能影响癌症复发,这是最近关注的一个课题。 流行病学研究表明,乳腺癌和前列腺癌的癌症复发情况因麻醉方案而异。 在这项研究中,我们根据 μ 阿片受体(MOR)调节 Lewis 肺癌(LLC)在细胞和动物模型中的致瘤性,确定了这些流行病学发现的可能机制。
我们使用人肺组织和人非小细胞肺癌(NSCLC)细胞系,通过免疫印迹和免疫组织化学分析评估 MOR 表达。 LLC 细胞用外周阿片受体拮抗剂甲基纳曲酮(MNTX)或 MOR shRNA 处理,并在体外评估增殖、侵袭和软琼脂集落形成,以及 C57BL/6 和 MOR 敲除小鼠中的原代肿瘤生长和肺转移,使用 VisEn 荧光介导断层扫描成像和免疫组织化学分析。
我们提供了几条证据表明,MOR 可能是一种潜在的肺癌治疗靶点,肺癌是一种死亡率高、治疗选择少的疾病。我们首先观察到,非小细胞肺癌患者的肺样本和几种人非小细胞肺癌细胞系中,MOR 的表达增加了 5-10 倍。MOR 激动剂吗啡和[D-Ala(2),N-MePhe(4),Gly-ol]-enkephalin(DAMGO)可促进体外 LLC 细胞生长。MNTX 处理或沉默 MOR 表达可抑制 LLC 侵袭和非锚定依赖性生长 50%-80%。注射沉默 MOR 的 LLC 导致小鼠肺转移减少约 65%。此外,与野生型对照相比,MOR 敲除小鼠注射 LLC 后不会形成明显的肿瘤。最后,持续输注外周阿片受体拮抗剂 MNTX 可抑制原代 LLC 肿瘤生长并减少肺转移。
综上所述,我们的数据表明阿片类药物可能对肺癌的进展有直接影响,并为流行病学发现提供了合理的解释。我们的观察结果进一步表明,阿片受体拮抗剂可能具有潜在的治疗作用。